Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus statement of the public health tuberculosis guidelines panel

JAMA

Volumn 279, Issue 12, 1998, Pages 943-948

  Chaulk, C Patrick ^a,b,c   Kazandjian, Vahe A ^b,d  

^a Annie E Casey Foundation   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Ctr for Performance Sciences Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0032565114     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.12.943     Document Type: Article

References (74)

1. Expanded tuberculosis surveillance and tuberculosis morbidity - United States, 1993. MMWR Morb Mortal Wkly Rep. 1994;43:361-365.
2. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. N Engl J Med. 1994;330:1703-1709.
3. Genewein A, Telenti A, Bernasconi C, et al. Molecular approach to identifying route of transmission of tuberculosis in the community. Lancet 1993;342: 841-844.
4. Aland D, Kalbut GE, Moss AR, et al. Transmission of tuberculosis in New York City. N Engl J Med. 1994;330:1710-1716.
5. Braden CR. Infectiousness of a university student with laryngeal and eavitary tuberculosis. Clin Infect Dis. 1995;21:565-570.
6. Arneil AS, Batterstill J. A mini-epidemic of tuberculosis in the Upper Fraser Valley Health Unit. Can J Public Health. 1973;64:497499.
7. Sacks JJ, Brenner ER, Breeden DC, Anders HM, Parker RL. Epidemiology of a tuberculosis outbreak in a South Carolina junior high school. Am J Public Health. 1985;75:361-365.
8. Kenyon TA, Valway SE, Ihle WW, Onorato IM, Castro KG. Transmission of multi-drug resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med. 1996;334:933-938.
9. Centers for Disease Control and Prevention. Improving Patient Adherence to Tuberculosis Treatment. Rev ed. Atlanta, Ga: Centers for Disease Control and Prevention, US Dept of Health and Human Services, Public Health Service; 1994.
10. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council forthe Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1993;42:1-8.
11. Combs DL, O'Brian RJ, Getter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, acceptability: the report of final results. Ann Intern Med. 1990;112:397-406.
12. Kent JH. The epidemiology of multidrug-resistant tuberculosis in the United States. Med Clin North Am. 1993;77:1391-1409.
13. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994;271:665-671.
14. Cleveland JL, Kent J, Gooch BF, et al. Multi-drug resistant Mycobacterium tuberculosis in an HIV dental clinic. Infect Control Hosp Epidemiol. 1995;16: 7-11.
15. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS. 1994;8:1103-1108.
16. Brown RE, Miller B, Taylor WR, et al. Health care expenditures for tuberculosis in the United States. Arch Intern Med. 1995;155:1595-1600.
17. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try. N Engl J Med, 1993;328:576-578.
18. Centers for Disease Control. Outbreak of multidrug resistant tuberculosis - Texas, California, and Pennsylvania. MMWR Morb Mortal Wkly Rep. 1990; 39:369-372.
19. Tuberculosis: The Federal Failure: Hearing Before the Human Resources and Intergovernmental Relations Subcommittee of the Committee on Government Operations, 102nd Cong, 2nd Sess (1993).
20. Selik RM, Chu SY, Buehler JW. HIV infection as leading cause of death among young adults in US cities and states. JAMA. 1993;263:2991-2994.
21. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: HIV, homelessness and the decline of TB control programs. Am Rev Respir Dis. 1991;144:745-749.
22. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. JAMA. 1993;270:65-68.
23. Centers for Disease Control. Tuberculosis among foreign-born persons entering the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. MMWR Morb Mortal Wkly Rep. 1990;39:8-12.
24. Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R. Drug resistant tuberculosis among the homeless in New York City. N Y State J Med. 1990;90:351-355.
25. Reichman LB, Felton CP, Edsall JR. Drug dependence: a possible new risk factor for tuberculosis disease. Arch Intern Med. 1979;139:337-339.
26. Sumartojo E. When tuberculosis treatment fails. Am Rev Respir Dis. 1993;147:1311-1320.
27. Seetha MA, Aneja KS. Problem of drug default and role of motivation. Indian J Public Health. 1982; 26:234-243.
28. Sloan JP, Sloan MC. An assessment of default and non-compliance in tuberculosis control in Pakistan. Trans R Soc Trop Med Hyg. 1981;75:717-718.
29. Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest. 1979;76: S741-S743.
30. Bloch AB, Simone PM, Leary LS, Hayden CH, Saggerson JJ, Castro KG. Completeness of tuberculosis (TB) therapy in the US, 1993 [abstract]. Am J Respir Crit Care Med. 1996;153:A333.
31. Centers for Disease Control and Prevention. Tuberculosis Program Management in the United States 1986-1991. Atlanta, Ga: Centers for Disease Control and Prevention; 1993.
32. Sbarbaro JA. The nature of man and physician. Am Rev Respir Dis. 1981;123:147.
33. Haynes BR, Taylor DW, Sacket DL. Compliancein Health Care. Baltimore, Md: The Johns Hopkins University Press; 1979.
34. Sbarbaro JA. Strategies to improve compliance with therapy. Am J Med. 1985;79(suppl 6A):34-37.
35. Sbarbaro JA. Compliance: Inducements and enforcements. Chest. 1979;76:750-756.
36. Sbarbaro JA, Sbarbaro JB. Compliance and supervision of chemotherapy of tuberculosis. Semin Respir Infect. 1994;9:120-127.
37. American Thoracic Society, Medical Section of the American Lung Association. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-1374.
38. Sorensen AA, Bialek RG. The Public Health Faculty/Agency Forum, Linking Graduate Education and Practice, Final Report. Atlanta, Ga: Bureau of Health Professions, Health Resources and Services Administration and Public Health Practice Program Office, Centers for Disease Control and Prevention; 1991.
39. Advisory Group: Council on Linkages Between Academia and Public Health Practice. Practice Guidelines for Public Health: Assessment of Scientific Evidence, Feasibility and Benefits: A Report of the Guideline Development Project for Public Health Practice. Albany, NY: Council on Linkages Between Academia and Public Health Practice; October 1995.
40. The World Health Organization. Report on the Tuberculosis Epidemic, 1997. Geneva, Switzerland: World Health Organization Global TB Programme; March 24, 1997.
41. Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 1992;102: 305s-311s.
42. Sukrakanchana-Trikham P, Puechal X, Rigal J, Rieder HL. Ten-year assessment of treatment outcome among Cambodian refugees with sputum smear-positive tuberculosis in Khao-l-Dang, Thailand. Tubercle Lung Dis. 1992;73:384-387.
43. Westaway MS, Conradie PW, Remmers L. Supervised out-patient treatment of tuberculosis: evaluation of a South African rural programme. Tubercule. 1991;72:140-144.
44. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet. 1994;343:647-648.
45. Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community-based short-course treatment of pulmonary tuberculosis in a developing nation: initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis. 1990;142:1301-1305.
46. Miles SH, Maat RB. A successful supervised outpatient short-course tuberculosis treatment program in an open refugee camp on the Thai-Cambodian Border. Am Rev Respir Dis. 1984;130:827-830.
47. Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med. 1995;151:1486-1490.
48. Kan G, Zhang L, Wu J, Ma Z. Supervised intermittent chemotherapy for pulmonary tuberculosis in a rural area of China. Tubercule. 1985;66:1-7.
49. El-Sadr W, Medard F, Barthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health. 1996;86: 1146-1149.
50. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274: 945-951.
51. Werhane MJ, Snukst-Torbeck G, Schraufnagel DE. The tuberculosis clinic. Chest. 1989;96:815-818.
52. Chan SL, Wong PC, Tam CM. 4-,5-and 6-Month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong. Tubercle Lung Dis. 1994;75:245-250.
53. Pozsik C, Kinney J, Breeden D, Nivin B, Davis T. Approaches to improving adherence to antituberculosis therapy - South Carolina and New York, 1986-1992. MMWR Morb Mortal Wkly Rep. 1993; 42:74-75, 81.
54. Cowie RL, Brink BA. Short-course chemotherapy for pulmonary tuberculosis with a rifampicin-isoniazid-pyrazinamide combination tablet S Afr Med J. 1990;77:390-391.
55. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990;112:407-415.
56. Caminero JA, Pavon JM, de Castro FR, et al. Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poorcompliance. Thotrax. 1996; 51:1130-1133.
57. Hong Kong Chest Service/British Medical Research Council. Study of a fully supervised programme of chemotherapy for pulmonary tuberculosis given once weekly in the continuation phase in the rural areas of Hong Kong. Tubercule. 1984;65: 5-15.
58. Wolde K, Lema E, Roscigno G, Abdi A. Fixed dose combination short course chemotherapy in the treatment of pulmonary tuberculosis. Ethiop Med J. 1992;30:63-68.
59. Menzies R, Rocher I, Vissandjee B. Factors associated with compliance in treatment of tuberculosis. Tubercle Lung Dis. 1993;74:32-37.
60. Snider DD, Long MW, Cross FS, Farer LS. Six-month isoniazid-rifampin therapy for pulmonary tuberculosis: report of a United States Public Health Service cooperative trial. Am Rev Respir Dis. 1984; 129:573-579.
61. Jin BW, Kim SC, Mori T, Shimao T. The impact of intensified supervisory activities on tuberculosis treatment. Tubercule Lung Dis. 1993;74:267-272.
62. Dutt AK, Moers D, Stead WW. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin: community physicians' seven-year experience with mainly outpatients. Am J Med. 1984;77:233-242.
63. Van der Werf TS, Dade GK, Van der Mark TW. Patient compliance with tuberculosis treatment in Ghana: factors influencing adherence to therapy in a rural service programme. Tubercule. 1990;71: 247-252.
64. Samuel GER. Use of discriminant analysis for improving treatment completion in district tuberculosis programme. Indian J Public Health. 1976; 20:21-24.
65. Armstrong RH, Pringle D. Compliance with anti-tuberculosis chemotherapy in Harare City. Cent Afr J Med. 1984;30:144-148.
66. Ormerod LP, McCarthy OR, Rudd RM, Horsfield N. Short course chemotherapy for pulmonary tuberculosis. Respir Med. 1991;85:291-294.
67. Valeza FS, McDougall AC. Blister calender packs for treatment of tuberculosis. Lancet. 1990; 335:473.
68. Moore RD, Chaulk CP, Griffiths R, Cavalcante S, Chaisson RE. Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med. 1996;154:1013-1019.
69. Burman WJ, Dalton CB, Cohn DL, Butler JRG, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest. 1997;112:63-70.
70. Chaulk CP. Preventive health care in six countries: models for reform? Health Care Financing Rev. 1994;15(4):7-19.
71. Liu K, Moon M, Sulvetta M, Chawla J. International infant mortality rankings: a look behind the numbers. Health Care Financing Rev. 1992;13(4):105-118.
72. Clinician's Handbook of Preventive Services: Put Prevention Into Practice. Washington, DC: US Dept of Health and Human Services, Public Health Service; 1994.
73. Rosenbaum S, Shin S, Smith BM, et al. Negotiating the New Health Care System: A Nationwide Study of Medicaid Managed Care Contracts. Washington, DC: George Washington University; 1997.
74. Centers for Disease Control and Prevention. Essential components of a tuberculosis prevention and control program. MMWR Morb Mortal Wkly Rep. 1995;44(No. RR-11):1-16.